A retrospective observational study to examine the clinical background and course of treatment-effective cases of immune checkpoint inhibitor with or without cytotoxic anticancer therapy as initial chemotherapy in advanced non-small cell lung cancer
Not Applicable
Recruiting
- Conditions
- advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000051395
- Lead Sponsor
- ational Hospital Organization Shikoku Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients have multiple cancers with a disease-free interval of less than 1 year at the time of ICI with or without chemo treatment. (Disease-free intervals are acceptable if the epithelial and intramucosal cancer lesions are judged to be curable by local treatment. (2) History of ICI treatment prior to initiation of ICI with or without chemo treatment. (iii) Recurrence after radical thoracic radiotherapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety of initial immune checkpoint inhibitor with or without cytotoxic chemotherapy
- Secondary Outcome Measures
Name Time Method